Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.
Type:
Grant
Filed:
July 21, 2010
Date of Patent:
July 15, 2014
Assignee:
Virginia Commonwealth University
Inventors:
Richard Thomas Marconi, Christopher Earnhart
Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.
Abstract: Cysteine-specific radiolabeled Cry1Fa protein retains insecticidal activity against insect pests and binds to insect brush border membrane vesicle receptors in a saturable manner. The biologically-active radiolabeled Cry1Fa protein is useful in competitive binding assays with other Cry toxins.
Type:
Grant
Filed:
December 16, 2011
Date of Patent:
July 8, 2014
Assignee:
Dow AgroSciences LLC
Inventors:
Steven L. Evans, Jianquan Li, Joel J. Sheets
Abstract: The present invention pertains to the protection against malaria. More particularly, the invention is based on the characterization of a novel liver and sporozoite-stage P. falciparum antigen, referred to as LSA-5. This antigen is highly antigenic and the prevalence of antibodies in subjects living in endemic areas is extremely high (ca. 90%). The invention concerns antigenic peptides, mixtures thereof, or polypeptides, mixotopes and conjugates comprising part of the sequence of LSA-5, as well as immunogenic compositions, vaccines and kits comprising these.
Type:
Grant
Filed:
June 13, 2006
Date of Patent:
July 1, 2014
Assignee:
Vac-4-All Pte. Ltd.
Inventors:
Pierre Druilhe, Karima Brahimi-Zeghidour
Abstract: The present disclosure relates to endophytic fungi from higher plants such as a Pteromischum sp. plant, and to extracts and compounds from such fungi that have desirable biological activities, such as antifungal and immunosuppressive activities. The present disclosure further relates to compositions comprising such extracts and compounds, as well as methods of making and using the compositions.
Type:
Grant
Filed:
November 14, 2011
Date of Patent:
July 1, 2014
Assignee:
The Regents of the University of California
Inventors:
Gary A. Strobel, Yuhao Ren, David B. Teplow
Abstract: Induction of tolerance to antigens by mucosal, preferably oral, delivery of the antigen in combination with an immunomodulating compound producing micro-organism is disclosed. More specifically, Foxp3+ and/or IL-10 and/or TGF-? producing regulatory T-cells are induced which are capable of suppressing undesired immune responses toward an antigen. The antigen is preferably delivered orally in combination with an immunosuppressing cytokine secreting micro-organism.
Abstract: The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.
Type:
Grant
Filed:
May 14, 2012
Date of Patent:
March 11, 2014
Assignee:
University of Stirling
Inventors:
Saravanane Poobalane, Kim Thompson, Alexandra Adams
Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
Type:
Grant
Filed:
September 12, 2012
Date of Patent:
February 18, 2014
Assignee:
Nationwide Children's Hospital, Inc.
Inventors:
Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
Abstract: The invention provides a process for producing glutathione or ?-glutamylcysteine by culturing in a medium a microorganism with a higher activity of a protein having an activity to transport intracellular glutathione to the outside of cells, and a higher activity of a protein involved in glutathione or ?-glutamylcysteine biosynthesis, compared with that of the parent strain, forming and accumulating glutathione or ?-glutamylcysteine in the medium, and recovering the glutathione or ?-glutamylcysteine from the culture.
Abstract: VACCIN AGAINST GROUP A BETA HEMOLYTIC STREPTOCOCCUS AND RESPECTIVE PROCESS FOR OBTAINING THEREOF, which predicts the production of recombinant protein cloned from the gene emm5, which contains a sequence of oligonucleotides corresponding to 52 and/or 87 amino acid residues capable of protection, isolated after the sequential molecular identification of the epitopes from the M protein carboxy-terminal region, differing in 01 amino acid residue, identified by antibodies and T lymphocytes of health human beings and of patients carriers of rheumatic fever, capable of generating a protective response by antibodies depending on the T lymphocytes; prevention of the development of the autoimmune disease by the selected epitope was evaluated in vitro with T lymphocytes from the cardiac tissue of patients with lesions arising out of rheumatic fever.
Type:
Grant
Filed:
July 19, 2007
Date of Patent:
February 4, 2014
Inventors:
Luiza Guilherme Guglielmi, Jorge Elias Kalil Filho
Abstract: An anti-obesity agent containing, as an active ingredient, a microorganism which belongs to the species Lactobacillus reuteri and is capable of producing lipases having the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5 or amino acid sequences having deletion, substitution or addition of one or more amino acids in the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5. The anti-obesity agent enables a patient to take a normal meal yet preventing the absorption of a fat into the body which is the primary cause of obesity.
Abstract: An anti-obesity agent containing, as an active ingredient, a microorganism which belongs to the species Lactobacillus reuteri and is capable of producing lipases having the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5 or amino acid sequences having deletion, substitution or addition of one or more amino acids in the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5. The anti-obesity agent enables a patient to take a normal meal yet preventing the absorption of a fat into the body which is the primary cause of obesity.
Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
Type:
Grant
Filed:
July 19, 2012
Date of Patent:
January 14, 2014
Assignees:
Nationwide Children's Hospital, Inc., The Board of Regents of the University of Oklahoma, Children's Hosptial Inc.
Inventors:
Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
Abstract: The present invention features a method for identifying an agent that inhibits Candida albicans-mediated differentiation of keratinocytes. Agents identified by the screening assay of the invention find application in the prevention and treatment of candidiasis.
Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
Inventors:
Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
Abstract: A method for preparing a xylose-utilizing strain of Saccharomyces cerevisiae and the Saccharomyces cerevisiae are introduced. The preferred recombinant strain contains multiple copies of integrated xylose metabolic genes, and can rapidly ferment xylose to produce ethanol from synthetic medium and lignocellulosic raw materials. The xylose-utilizing strain is applicable for the cellulosic ethanol production industry and brewing industry.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
December 10, 2013
Assignee:
Institute of Nuclear Energy Research Atomic Energy Council, Executive Yuan
Abstract: This invention relates to improved methods for purifying polysaccharides from cellular components, such as a cell wall. The method relates to hydrolyzing and separating the polysaccharides, thereby resulting in purified polysaccharides useful for producing antigens, antibodies, and vaccines comprising the polysaccharides alone or conjugated to carrier molecules. This method is simple, rapid, efficient, scalable, and reproducible.
Type:
Grant
Filed:
January 12, 2007
Date of Patent:
December 3, 2013
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The invention encompasses phage ?mru including phage induction, phage particles, and the phage genome. Also encompassed are phage polypeptides, as well as polynucleotides which encode these polypeptides, expression vectors comprising these polynucleotides, and host cells comprising these vectors. The invention further encompasses compositions and methods for detecting, targeting, permeabilising, and inhibiting microbial cells, especially methanogen cells, using the disclosed phage, polypeptides, polynucleotides, expression vectors, or host cells.
Type:
Grant
Filed:
September 25, 2008
Date of Patent:
November 26, 2013
Assignee:
Pastoral Greenhouse Research Limited
Inventors:
Eric Heinz Altermann, Graeme Trevor Attwood, Sinead Christine Leahy, William John Kelly, Robert Starr Ronimus, Dong Li, Zhanhao Kong, Linley Rose Schofield, Debjit Dey, Catherine Mary Tootill, Carrie Sang, Christina Diane Moon, Petrus Hendricus Janssen
Abstract: Method for producing multiple modifications in the chromosome of Gram-negative bacteria and Salmonella strains which are deficient in c-di-GMP synthesis obtained by said method. The method can be used to make multiple modifications in the genome of Gram-negative bacteria, simply and efficiently, using the plasmids of the invention, which comprise a marker gene under the control of a constitutive promoter, a replication origin specific for Gram-negative bacteria, a gene which encodes a heat-sensitive protein essential for initiating replication of the plasmid, making the replication origin heat-sensitive, and a counter-selection gene. The invention also relates to mutant Salmonella enterica strains obtained using the method of the invention in which some of the twelve genes which encode proteins with GGDEF domain have been selected*, and to the use thereof as expression vectors, immunotherapeutic agents and in metabolic studies.
Type:
Grant
Filed:
May 21, 2010
Date of Patent:
November 19, 2013
Assignees:
Universidad Publica de Navarra, Consejo Superior de Investigaciones Cientificas